Technology appraisal committee meeting (committee D)

06 June 2024

via Zoom

Draft Agenda

The meeting will take place via Zoom, a secure web conferencing tool.

You will need to join the meeting by 9:00am and it is expected to finish at approximately 5:00pm, although this may be subject to change.

Please note that this agenda is draft and is subject to change before the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
  4. Minutes from the last committee meeting held on 9 May 2024 – Part 1 only (open session)
  5. Appraisal of fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]​​
    • 5.1. Introduction by the Chair, Raju Reddy – Part 2 only (open session)
    • 5.2. Declaration of interests – Part 1 only (open session)
    • 5.3. Presentation by the lead team, Dr Philip Mallender, Dr Bernard Khoo and Paul Caufield – Part 1 AND part (open and closed session)
    • 5.4. Agreement on the content of the  Draft Guidance (DG) or Final Draft Guidance (FDG) – Part 2 only (closed session)
  6. Appraisal of osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]​​
    • 61. Introduction by the Chair, Dr Megan John – Part 1 only (open session)
    • 6.2. Declaration of interests – Part 1 only (open session)
    • 6.3. Presentation by lead team - Professor Sofia Dias, Martin Bradley and Paul Caufield – Part 1 AND part 2  (open and closed session)
    • 6.4. Agreement on the content of the  Draft Guidance (DG) or Final Draft Guidance (FDG) – Part 2 only (closed session)
  7. Appraisal of ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]
    7.1. Introduction by the Chair, Dr Megan John – Part 1 only (open session)
    7.2. Declaration of interests – Part 1 only (open session)
    7.3. Presentation by the Chair, Dr Megan John – Part 1 AND part 2 (open and closed session)
    7.4. Agreement on the content of the  Draft Guidance (DG) or Final Draft Guidance (FDG) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Important information on how to register

  • Click on the registration link at the bottom of the page and complete the Zoom registration form, selecting the topic you would like to observe. Please register with your full name as this is how it will be displayed during the committee meeting and please choose ‘Public observer’ as the attendee type.
  • You must use the email address that you are registering with to join the meeting. Please ensure you type in the correct address. Also check that if you are using a work email address, that it supports the use of Zoom. If in doubt, use a personal email address.
  • Registration will close at 4:00pm on Thursday 3 May 2024.
  • You will receive your joining link 1-2 days before the meeting with the time you need to join. You must click on the link to join, NOT use the ID and password.
  • Please keep the link in a safe and in an accessible place for the meeting to minimise any delay on the day.
  • Joining instructions will also be sent to you 1-2 days before the meeting.
  • We will not be able to accept any late requests or name changes after registration closes.
  • As a public observer, you will be able to listen to the business of the meeting, except where confidential information is being discussed. However, you will not be able to participate in the committee's discussions or ask questions, take part in voting, or put your views to the members of the committee.
  • Please read through our common questions and answers about meetings in public document for further information on virtual meetings.

Privacy statement – These meetings are being held via Zoom either as a meeting or webinar and your name, email and IP address will be processed. We ask for this data to help facilitate the event and monitor attendance. We also ask you to share any accessibility needs that would support you during the virtual meeting. If the web meeting you are attending offers an interactive poll or Q&A session, participation is not mandatory, however your name may be processed with your poll responses and questions. We store this information in Zoom for 6 months, after which it is automatically deleted. After you have attended a meeting, we may also send you a feedback form so you can tell us about your experience and help us make any improvements. The feedback is anonymous and you cannot be identified. Further information about how we manage personal data at NICE can be found on our privacy notice – https://www.nice.org.uk/privacy-notice

Should you have any queries regarding observing this meeting, please contact the Meetings in Public Coordinator.

Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.

    REGISTRATION IS OPEN​​

    As you are registering directly on Zoom, your place is guaranteed so you will not receive a confirmation or approval email. Please make sure you note the meeting date/time in your diary, and you will receive your Zoom joining links and further instructions 1-2 days before the meeting.

    Register here:

    Topic 1: Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    Topic 2: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    Topic 3: Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

    Date and time of next meeting

    The next meeting will take place on Wednesday 3 July 2024 at 9:00am via Zoom.

    Please note all timings are approximate.